# Intravenous Edotecarin in Patients With Advanced Gastric Cancer That Has Progressed or Recurred After Chemotherapy

> **NCT00087503** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 28 (—)

## Conditions studied

- Stomach Neoplasms

## Interventions

- **DRUG:** Edotecarin

## Key facts

- **NCT ID:** NCT00087503
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 28 (—)
- **Last updated:** 2008-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00087503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00087503, "Intravenous Edotecarin in Patients With Advanced Gastric Cancer That Has Progressed or Recurred After Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00087503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*